Publications (547) María Victoria Mateos Manteca publications

filter_list

2025

  1. Accelerating Myeloma Drug Development: Will Minimal Residual Disease Replace Progression-Free Survival as an Intermediate Surrogate End Point?

    Journal of Clinical Oncology

  2. Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trial

    The Lancet Oncology

  3. Clinical impact of [18F]FDG-PET/CT in ARI0002h treatment, a CAR-T against BCMA for relapsed/refractory multiple myeloma

    Blood Advances, Vol. 9, Núm. 3, pp. 571-582

  4. Clinical significance of complete remission and measurable residual disease in relapsed/refractory multiple myeloma patients treated with T-cell redirecting immunotherapy

    American Journal of Hematology, Vol. 100, Núm. 1, pp. 93-102

  5. Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma

    Journal of Clinical Oncology

  6. Correction to: The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development (Blood Cancer Journal, (2025), 15, 1, (15), 10.1038/s41408-025-01212-0)

    Blood Cancer Journal

  7. Daratumumab: a game changer in early myeloma

    Blood

  8. European Myeloma Network Group review and consensus statement on primary plasma cell leukemia

    Annals of Oncology, Vol. 36, Núm. 4, pp. 361-374

  9. Evolution of frontline treatment for multiple myeloma: clinical investigation of quadruplets containing carfilzomib and anti-CD38 monoclonal antibodies

    Annals of Hematology

  10. Health-Related Quality of Life in Patients With Relapsed/Refractory Multiple Myeloma Treated With Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone: An Analysis of Patient-Reported Outcomes From the Phase 3 CANDOR Trial

    Clinical Lymphoma, Myeloma and Leukemia

  11. Is t(11;14) Always a Standard-Risk Cytogenetic Abnormality? Results From GEM05MENOS65 and GEM2012 PETHEMA/GEM Transplantation Trials

    Clinical Lymphoma, Myeloma and Leukemia

  12. Minimally Invasive Assessment of Peripheral Residual Disease during Maintenance or Observation in Transplant-Eligible Patients with Multiple Myeloma

    Journal of Clinical Oncology, Vol. 43, Núm. 2, pp. 125-132

  13. Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1–2 study

    The Lancet Haematology, Vol. 12, Núm. 4, pp. e269-e281

  14. Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma

    New England Journal of Medicine, Vol. 392, Núm. 2, pp. 138-149

  15. The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development

    Blood cancer journal, Vol. 15, Núm. 1, pp. 15

2024

  1. 30-Minute infusion of isatuximab in patients with newly diagnosed multiple myeloma: Results of a Phase 1b study analysis

    HemaSphere

  2. A research center’s experience of T-cell–redirecting therapies in triple-class refractory multiple myeloma

    Blood Advances, Vol. 8, Núm. 13, pp. 3478-3487

  3. ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma: final results of a phase I/IIa study

    Haematologica, Vol. 109, Núm. 3, pp. 867-876

  4. An open-label, first-in-human, single agent, dose escalation study for the evaluation of safety and efficacy of SAR442085 in patients with relapsed or refractory multiple myeloma

    European Journal of Haematology, Vol. 113, Núm. 5, pp. 593-605

  5. Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma

    New England Journal of Medicine, Vol. 391, Núm. 5, pp. 393-407